



Article

# The Different Microbial Etiology of Prosthetic Joint Infections according to Route of Acquisition and Time after Prosthesis Implantation, Including the Role of Multidrug-Resistant Organisms

Natividad Benito <sup>1,2,\*</sup>, Isabel Mur <sup>1,2</sup>, Alba Ribera <sup>3</sup>, Alex Soriano <sup>4</sup>, Dolors Rodríguez-Pardo <sup>5</sup>, Luisa Sorlí <sup>6</sup>, Javier Cobo <sup>7</sup>, Marta Fernández-Sampedro <sup>8</sup>, María Dolores del Toro <sup>9</sup>, Laura Guío <sup>10</sup>, Julia Praena <sup>11</sup>, Alberto Bahamonde <sup>12</sup>, Melchor Riera <sup>13</sup>, Jaime Esteban <sup>14</sup>, Josu Mirena Baraia-Etxaburu <sup>15</sup>, Jesús Martínez-Alvarez <sup>16</sup>, Alfredo Jover-Sáenz <sup>17</sup>, Carlos Dueñas <sup>18</sup>, Antonio Ramos <sup>19</sup>, Beatriz Sobrino <sup>20</sup>, Gorane Euba <sup>3</sup>, Laura Morata <sup>4</sup>, Carles Pigrau <sup>5</sup>, Juan P. Horcajada <sup>6</sup>, Pere Coll <sup>2,21</sup>, Xavier Crusi <sup>22</sup>, Javier Ariza <sup>3</sup> and on behalf of the REIPI (Spanish Network for Research in Infectious Disease) Group for the Study of Prosthetic Joint Infections/GEIO (Group for the Study of Osteoarticular Infections), SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology) †

<sup>1</sup> Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau - Institut d'Investigació Biomèdica Sant Pau, 08025 Barcelona, Spain; imur@santpau.cat

<sup>2</sup> Department of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain; pcoll@santpau.cat

<sup>3</sup> Department of Infectious Diseases, Hospital Universitari Bellvitge, 08097 Barcelona, Spain;  
albaribera@gmail.com (A.R.); geubuga@gmail.com (G.E.); jariza@bellvitgehospital.cat (J.A.)

<sup>4</sup> Department of Infectious Diseases, Hospital Clínic Universitari, 08036 Barcelona, Spain;  
asoriano@clinic.cat (A.S.); lmorata@clinic.cat (L.M.)

<sup>5</sup> Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain;  
dolorodriguez@vhebron.net (D.R.-P.); cpigrau@vhebron.net (C.P.)

<sup>6</sup> Department of Infectious Diseases, Parc de Salut Mar, 08003 Barcelona, Spain;  
lisorli@parcdesalutmar.cat (L.S.); jhorcajada@parcdesalutmar.cat (J.P.H.)

<sup>7</sup> Department of Infectious Diseases, Hospital Universitario Ramón y Cajal – IRYCIS, 28034 Madrid, Spain;  
javier.cobo@salud.madrid.org

<sup>8</sup> Department of Infectious Diseases, Hospital Universitari Valdecilla, 39008 Santander, Spain;  
martafersam@yahoo.es

<sup>9</sup> Department of Infectious Diseases, Clinical Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain; mdeltoro@us.es

<sup>10</sup> Department of Infectious Diseases, Hospital Universitario Cruces, 48903 Bilbao, Spain;  
laura.guiocarrion@osakidetza.eus

<sup>11</sup> Department of Infectious Diseases, Clinical Microbiology and Preventive Medicine, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; juliapraena@gmail.com

<sup>12</sup> Department of Internal Medicine-Infectious Diseases, Hospital Universitario del Bierzo, 24404 León, Spain;  
med007783@me.com

<sup>13</sup> Infectious Diseases Unit, Department of Internal Medicine, Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain; melchor.riera@ssib.es

<sup>14</sup> Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain;  
jestebanmoreno@gmail.com

<sup>15</sup> Department of Infectious Diseases, Hospital Universitario de Basurto, 48013 Bilbao, Spain;  
josumirena.baraia-etxaburuartexe@osakidetza.eus

<sup>16</sup> Department of Orthopedic and Traumatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; j.martinez-alvarez@hotmail.com

<sup>17</sup> Unit of Nosocomial Infection, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain;  
ajover.lleida.ics@gencat.cat

<sup>18</sup> Department of Internal Medicine, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain;  
carlos.duenas@hotmail.com

- 19 Infectious Diseases Unit, Department of Internal Medicine, Hospital Universitario Puerta de Hierro,  
28222 Madrid, Spain; aramos220@gmail.com
- 20 Department of Infectious Diseases, Hospital Regional Universitario Málaga, 29010 Málaga, Spain;  
bea\_sobrino@yahoo.es
- 21 Department of Clinical Microbiology, Hospital de la Santa Creu i Sant Pau - Institut d'Investigació  
Biomèdica Sant Pau, 08025 Barcelona, Spain
- 22 Department of Orthopedic and Traumatology, Hospital de la Santa Creu i Sant Pau - Institut d'Investigació  
Biomèdica Sant Pau, 08025 Barcelona, Spain; xcrusi@santpau.cat
- \* Correspondence: nbenito@santpau.cat; Tel.: +34-935-565-624; Fax: +34-935-565-938
- † Members of the Group (in alphabetical order): Hospital Universitari Arnau de Vilanova, Lleida: Mercé  
García-González, Ferran Pérez-Villar, Laura Prats-Gispert, María Ramírez-Hidalgo. Hospital Universitario  
de Basurto, Bilbao: Mireia De-la-Peña-Trigueros, Iñigo López-Azkarreta, Miriam López-Martínez. Hospital  
Universitari de Bellvitge, Barcelona: Jaime Lora-Tamayo (currently, Hospital 12 de Octubre), Oscar Murillo,  
Salvador Pedrero. Hospital el Bierzo, León: Juan Amador, Luis García-Páino, Susana Parrondo, Carmen  
Raya. Hospital Universitario Central de Asturias, Oviedo: Alfonso Moreno. Hospital Universitario de  
Burgos, Burgos: María Aránzazu Blanco-Martínez-de-Morentín, Laura Rodríguez-Fernández Genoveva  
Zapico-Aldea. Hospital Clínic Universitari, Barcelona: Luis Lozano, Ernesto Muñoz-Mahamud. Hospital  
Universitario Cruces, Bilbao: Josu Merino-Pérez. Parc de Salut Mar, Barcelona: Albert Alier, Núria Prim,  
Luis Puig. IIS-Fundación Jiménez Díaz: Álvaro Auñón, Antonio Blanco, Joaquín García-Cañete, Raul  
Parrón-Cambero. Hospital Universitario Marqués de Valdecilla, Santander: M Carmen Fariñas, Ricardo  
Manuel-Bloque, Carlos Salas-Venero. Hospital Universitario Puerta de Hierro: Jesús Campo-Loarte, Elena  
Múñez-Rubio, Isabel Sánchez-Romero. Hospital Universitario Ramón y Cajal, Madrid: Rosa  
Escudero-Sánchez, Patricia Ruiz-Carbajosa. Hospital de la Santa Creu i Sant Pau, Barcelona: Aránzazu  
González, José Carlos González, Marcos Jordán, Alba Rivera. Hospital Universitario Son Espases, Palma de  
Mallorca: Carmen Marinescu, Francisco Montaner, Antonio Ramírez. Hospital Universitari Vall d'Hebron,  
Barcelona: Pablo S. Corona, Maily Lung, Mireia Puig-Asensio. Hospital Universitario Virgen Macarena,  
Sevilla: Miguel Ángel Munain-Ezcurra, Cecilia Peñas-Espinar, Ana Isabel Suárez. Hospital Universitario  
Virgen del Rocío, Sevilla: María José Gómez, Macarena López-Pliego.

Received: 17 April 2019; Accepted: 9 May 2019; Published: 13 May 2019



**Abstract:** The aim of our study was to characterize the etiology of prosthetic joint infections (PJIs)—including multidrug-resistant organisms (MDRO)—by category of infection. A multicenter study of 2544 patients with PJIs was performed. We analyzed the causative microorganisms according to the Tsukayama's scheme (early postoperative, late chronic, and acute hematogenous infections (EPI, LCI, AHI) and “positive intraoperative cultures” (PIC)). Non-hematogenous PJIs were also evaluated according to time since surgery: <1 month, 2–3 months, 4–12 months, >12 months. AHIs were mostly caused by *Staphylococcus aureus* (39.2%) and streptococci (30.2%). EPIs were characterized by a preponderance of virulent microorganisms (*S. aureus*, Gram-negative bacilli (GNB), enterococci), MDROs (24%) and polymicrobial infections (27.4%). Conversely, coagulase-negative staphylococci (CoNS) and *Cutibacterium* species were predominant in LCIs (54.5% and 6.1%, respectively) and PICs (57.1% and 15.1%). The percentage of MDROs isolated in EPIs was more than three times the percentage isolated in LCIs (7.8%) and more than twice the proportion found in AHI (10.9%). There was a significant decreasing linear trend over the four time intervals post-surgery for virulent microorganisms, MDROs, and polymicrobial infections, and a rising trend for CoNS, streptococci and *Cutibacterium* spp. The observed differences have important implications for the empirical antimicrobial treatment of PJIs.

**Keywords:** prosthetic joint infections; microbial etiology; classification schemes for prosthetic joint infections; antimicrobial empirical treatment; multidrug-resistant organisms

## 1. Introduction

While the risk of prosthetic infection in patients undergoing joint replacement could be considered low (hips: 0.2–1.5%, knees: 0.4–1.5%, shoulders: 0.8–2%), the high frequency of these procedures converts the combination of low risks into a substantial burden of infection [1]. Prosthetic joint infection (PJI) is a devastating complication associated with major patient morbidity and high healthcare and societal costs (recent estimated costs of 20,000–40,000 dollars per infection) [1].

Biofilm formation when microorganisms attach to the surface of prosthetic devices plays a crucial role in the pathogenesis of PJI [2]. This poses a challenge for the diagnosis of biofilm-embedded microorganisms, and antimicrobial therapy in biofilm-associated pathogens is of limited efficacy [3].

Antimicrobial therapy combined with surgery is required to cure PJs [4–7]. A common management approach is to start broad-spectrum antimicrobial agents after obtaining intraoperative samples for culture [8,9]. The importance of adequate initial empirical antimicrobial therapy in the outcome of infections is well-known [10] and seems to be critical in patients with PJs treated with debridement, antibiotics, and implant retention [11]. Vancomycin combined with a broad-spectrum beta-lactam such as piperacillin-tazobactam has been recently studied as an initial treatment [12,13] but has been associated with a high rate of adverse effects [13]. After the pathogen has been identified and antimicrobial susceptibility results are available, the most effective narrow-spectrum antibiotic regimen is selected for continuation of therapy [4–8,10]. Nevertheless, a significant number of patients (5–35%) have negative cultures [8]. In this situation, empirical antimicrobial therapy is even more important, but more difficult to decide on, taking into consideration that the patient will have to receive it for the several weeks to months that it takes to cure a PJI [4,8].

Knowledge of the microbiological spectrum of PJs is essential for guiding empirical antibiotic therapy. There are, however, no specific recommendations for the most appropriate empirical treatment for PJs. We previously characterized the microbial etiology of PJI in a large cohort of patients [14], but the causative microorganisms can vary significantly, depending on the infection route and the time interval between index surgery and onset of symptoms, which can help guide empirical treatment [4,8,12,15]. These differences may include the involvement of multidrug-resistant microorganisms (MDRO), although this aspect has not been previously studied. There are several useful classifications of PJI in different categories, namely based on the mode of acquisition and/or time from prosthesis implantation, but none of them are universally accepted [8,16]. A good deal of what is currently known about the microbial etiology of different categories of PJI is based on studies that are limited by small sample sizes [11,15,17–31] and describe single-center experiences [12,15,17–24,26–28,30–32]. Most focus on specific types of infection, [11,21,23,25,29] surgical strategies used during treatment [22,31], or include only infections occurring within a limited period of time after prosthesis implantation [30,33]. Consequently, the results do not adequately represent the percentages of the different microorganisms involved in different types of infection across the full range of PJs.

Our aim was to characterize the etiology of PJs—including MDROs—according to the category of infection, in a large cohort of consecutive patients with PJs. The results would enable tailoring empirical antimicrobial therapy to the clinical situation, offering coverage of the most likely microorganisms but narrowing the antimicrobial spectrum, which is crucial in antimicrobial stewardship program, and potentially reducing adverse effects.

## 2. Methods

### 2.1. Setting, Study Design, and Patients

This was an ambi-directional observational study carried out at 19 hospitals in different areas of Spain. The study was performed within the framework of the Spanish Network for Research in Infectious Diseases (REIPI) ([www.reipi.org](http://www.reipi.org)) and included the participation of the Group for the Study of Osteoarticular Infections (GEIO) (<https://seimc.org/grupos-de-estudio/geio>) belonging to the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). The REIPI Group for the

Study of PJs and the GEIO form a multicenter collaborative group of infectious disease specialists, microbiologists, and orthopedic specialists across Spain, with extensive experience at orthopedic infection management and had previous joint publications [14,29,34–36].

All consecutive adult patients diagnosed with PJs between 2003 and 2012 were included. Excluded were relapse episodes of infections that were first diagnosed before the study period.

## 2.2. Data Collection

This study was ambi-directional, with both prospective and retrospective data collection. Data were first acquired from the REIPI cohort of consecutive patients with PJI who were prospectively enrolled from 2003 through 2006. The cohort characteristics have been described elsewhere [29,34]. Apart from clarifications concerning key variables, no further data on this prospective cohort was requested. For the retrospective phase, data of patients who developed PJs from 2007 through 2012 were retrospectively collected from REIPI and other hospitals that met the criteria for participation. The three criteria included hospitals with orthopedic surgery, the use of proper identification procedures to ensure the inclusion of all consecutive cases diagnosed at the hospital, and that ascertainment bias was minimized, and finally, most of the data needed to resolve queries were either available or easily accessible. A standard case report form designed specifically for this study was used at all sites to collect data. Data of patients with PJI were obtained from electronic databases used at most of the participating hospitals with prospectively collected information on patients with PJI, and from the patient's medical records held at each hospital as required. Completed case report forms were sent to the coordinating center for data entry, or the site investigators entered the variables directly into the common electronic database. The coordinating center for this study was the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain). The study was approved by the Institutional Review Board at the Hospital de la Santa Creu i Sant Pau before data collection started. All case report forms were reviewed at the coordinating center.

## 2.3. Clinical Data and Definitions

The following information was collected: Patient demographics and underlying conditions, characteristics of the arthroplasty, risk factors for MDROs, classification of the PJI, and microbiological diagnosis. All variables were predefined to ensure standardized data collection in participating hospitals. Individual patient data recorded included age and gender; comorbidities and immunosuppressive therapy; the patient's American Society of Anesthesiologists (ASA) score before the surgical procedure (typically the arthroplasty implant) closest to the diagnosis of infection; previous exposure to antibiotics ( $\geq 7$  days) or hospitalization in the previous 90 days ( $\geq 2$  days); receipt of hemodialysis, intravenous therapy, wound care or specialized nursing care at home in the 30 days preceding the last surgical procedure or onset of hematogenous PJI; residence in a nursing home or long-term care facility. Information of the arthroplasty collected included: The reasons for implantation and the date performed, site, time from admission to implantation, primary or revision arthroplasty, cemented vs. uncemented, and the use of antibiotic-loaded bone cement. Date of diagnosis, classification of the PJI type, and the number of cultured samples and their results were also recorded.

Cefazolin —sometimes cefuroxime, depending on the center, — was used as an antimicrobial prophylaxis in surgery. Vancomycin or teicoplanin was used for patients who were allergic to penicillin. Baseline comorbidities were quantified using the Charlson comorbidity score [37]. A diagnosis of PJI was established using the 2011 Musculoskeletal Infection Society definition [38]. The microbial etiology of PJI was established when the same organism (indistinguishable by common laboratory tests including genus and species identification or common antibiogram) was isolated in two or more periprosthetic cultures yielded [4]. When the diagnostic criteria for PJI were met, virulent microorganisms (such as *Staphylococcus aureus*) isolated in a single periprosthetic tissue/biopsy sample were also considered causative organisms [7]. MDRO was defined following Magiorakos et al. (acquired non-susceptibility to at least one agent in three or more specified antimicrobial categories) [39].

The Tsukayama scheme was used to classify PJs. This scheme divides PJs into four categories, based partly on presumed mode of infection and time since surgery: [15,40] a) Early postoperative infection (EPI): PJ diagnosed within one month of the index surgery (usually implantation of joint prosthesis, but also later procedures performed at the arthroplasty site); b) late chronic infection (LCI): PJs with an insidious clinical course diagnosed >1 month after the index operation; both EPI and LCI are considered perioperatively acquired; c) acute hematogenous infection (AHI): PJ associated with documented or suspected antecedent bacteremia and characterized by acute onset of symptoms in the affected joint with the prosthesis; d) positive intraoperative culture (PIC): PJ diagnosed when at least two specimens, from a minimum of five obtained at the time of revision surgery, are positive after culture; infection was not clinically obvious or suspected at the time of the revision [15,40]. AHI and PIC can occur any time after surgery. EPI and AHI are acute PJs that can be treated and potentially cured with debridement and antibiotics, without removal of the prosthesis. Another commonly used classification scheme based only on time since index surgery classifies PJs as early (develops <3 months after surgery), delayed (3 to 12 or 24 months after surgery), or late (>12 or 24 months after surgery) [8,41]. This chronological framework was used to further analyse all cases of non-hematogenous PJ.

#### 2.4. Statistical Analysis

Medians and interquartile ranges were used to summarize continuous variables, and absolute numbers and percentages of total samples for categorical variables. Statistical analyses were based on differences in the percentages of causative microorganisms/groups of organisms of PJ in the four categories of the Tsukayama scheme (EPI, LCI, AHI, PIC). The causative microorganisms of non-haematogenous PJs diagnosed according to time since surgery (within the first month, in months 2/3, months 4–12, and more than 12 months after the index surgery), were also compared. These percentages were compared using the  $\chi^2$  test or Fisher's exact test as appropriate. To determine statistically significant linear trends in the proportions of infection caused by specific microorganisms/groups of organisms over time the Mantel-Haenszel  $\chi^2$  test for trend was used. The data were analyzed using SPSS, version 22.0 (IBM SPSS, Chicago, IL, USA)

### 3. Results

Overall, 2524 episodes of PJ were diagnosed during the study period in 19 participating hospitals located in eight of the 17 administrative regions of Spain. All were university hospitals except for one. In 17 hospitals, they had more than 500 beds, and two had between 400 and 500 beds.

The characteristics of the patients are outlined in Table 1. Most infections occurred in hip or knee arthroplasties; 77.2% affected primary arthroplasties. The most common reason for joint replacement was degenerative joint disease.

LCI was the most frequent type of infection, accounting for 47.4% (1178) of cases, followed by EPI (35.7%, 888), AHI (11.6%, 288) and PIC (5.3%).

A microbiological diagnosis was obtained in 2288 cases (90.6%) and significantly more frequently in EPI (94.5%, 839) and AHI (92%, 256) than in LCI (89.3%, 1052) ( $p < 0.001$ ).

The causative microorganisms of PJ using Tsukayama's classification are shown in Tables 2 and 3. Overall, coagulase-negative staphylococci (CoNS) were the most common group of microorganisms involved in PJ (with *Staphylococcus epidermidis* as the most frequent species). They were more often isolated in chronic (>50% of cases) than in acute infections. Whereas CoNS represented almost 30% of EPIs, they were involved in less than 10% of AHI. *S. aureus* on the other hand, was the microorganism most often involved in acute infection and the leading causative species of EPI and AHI. Streptococci were significantly more common in AHI, while enterococci were more frequent in EPI than in other categories of PJ.

**Table 1.** Characteristics of patients with prosthetic joint infection diagnosed between 2003 and 2012.

Characteristic	No. of Cases (n = 2524)
Median age (IQR), years	74 (13)
Female gender	1508 (59.7)
Underlying conditions	
• Any comorbid condition	1594 (63.3)
• Diabetes mellitus	592 (23.5)
• Heart disease	506 (20.1)
• Chronic obstructive pulmonary disease	299 (11.9)
• Cancer	231 (9.2)
• Neurological disease	221 (8.8)
• Chronic kidney disease	195 (7.7)
• Systemic rheumatic (connective tissue) disease	175 (6.9)
• Immunosuppressive treatment	168 (6.7)
• Liver disease	164 (6.5)
• Rheumatoid arthritis	129 (5.1)
Charlson score, median (IQR)	1 (2)
Index arthroplasty site	
• Hip	1244 (49.3)
○ Hemiarthroplasty	249 (9.9)
○ Total arthroplasty	995 (39.5)
• Knee	1219 (48.3)
• Shoulder	46 (1.8)
• Other	15 (0.6)
ASA score, median (IQR)	2 (1)
Indication for index arthroplasty*	
• Primary joint replacement	1938 (77.2)
○ Osteoarthritis	1264 (52.4)
○ Fracture	417 (17.3)
○ Avascular necrosis	51 (2.1)
○ Rheumatoid arthritis	32 (1.3)
○ Tumor	31 (1.3)
○ Septic arthritis sequelae	12 (0.5)
○ Other	43 (1.8)
• Revision arthroplasty (prior joint arthroplasty)	573 (22.8)
○ Aseptic loosening	292 (12.1)
○ Infection	158 (6.6)
○ Dislocation	32 (1.3)
○ Periprosthetic fracture	25 (1)
○ Implant failure or fracture	13 (0.5)
○ Other	29 (1.2)

Unless stated otherwise, data refer to numbers (%) of patients with the indicated characteristic. ASA = American Society of Anesthesiologists; IQR = interquartile range. \* Information on indication for index arthroplasty was not available for 112 (4.4%) procedures.

Aerobic Gram-negative bacilli (GNB), both *Enterobacteriaceae* and non-fermenting Gram-negative bacilli, were much more frequently involved in EPI than in the other types of infection. *Escherichia coli*, however, was isolated almost as frequently in AHI as in EPI.

*Cutibacterium* (formerly *Propionibacterium*) spp. were more common in chronic than in acute PJI, but with a significantly higher proportion in the PIC group (15.1%) than in the LCI (6.1%).

Polymicrobial infections were much more frequent in the EPI category (27.4%) than in other types, and MDROs (both methicillin-resistant *S. aureus* (MRSA) and multidrug-resistant GNB, including extended-spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*) were also much more commonly isolated in EPIs than in other categories of infection. Ciprofloxacin-resistant GNB were also more common in EPIs.

**Table 2.** Aerobic Gram-positive cocci involved in prosthetic joint infections using the four categories of the Tsukayama classification.

Microorganism or Microorganism Group	Early Postoperative Infections n = 839	Acute Hematogenous Infections n = 265	Late Chronic Infections n = 1052	Positive Intraoperative Cultures n = 126	p-Value
	Total no. (%)*				
<i>Staphylococcus</i> species	505 (60.2)	122 (46)	776 (73.8)	84 (66.7)	<0.001
• Coagulase-negative Staphylococci (CoNS)	236 (28.1)	23 (8.7)	573 (54.5)	72 (57.1)	<0.001
○ <i>Staphylococcus epidermidis</i>	130 (15.5)	11 (4.2)	355 (33.7)	36 (28.6)	<0.001
○ <i>Staphylococcus lugdunensis</i>	2 (0.2)	6 (2.3)	31 (2.9)	4 (3.2)	<0.001
○ <i>Staphylococcus capitis</i>	8 (1)	0 (0)	25 (2)	2 (1.6)	0.014
○ <i>Staphylococcus hominis</i>	8 (1)	0 (0)	22 (2.1)	0 (0)	0.014
○ <i>Staphylococcus warneri</i>	5 (0.6)	0 (0)	11 (1)	3 (2.4)	0.065
○ <i>Staphylococcus auricularis</i>	2 (0.2)	0 (0)	12 (1.1)	1 (0.8)	0.048
○ CoNS not identified to species level	89 (10.6)	6 (2.3)	168 (16)	23 (23)	<0.001
• <i>Staphylococcus aureus</i>	299 (35.6)	104 (39.2)	224 (21.3)	12 (9.5)	<0.001
<i>Streptococcus</i> species	36 (4.3)	80 (30.2)	85 (8.1)	5 (4)	<0.001
• <i>Streptococcus agalactiae</i>	8 (1)	28 (10.9)	28 (2.7)	0 (0)	<0.001
• Viridans group streptococci not identified to species level	6 (0.7)	12 (4.5)	25 (2.4)	2 (1.6)	0.002
• <i>Streptococcus mitis</i> group	8 (1)	5 (1.9)	16 (1.5)	2 (1.6)	0.632
• <i>Streptococcus anginosus</i> group	3 (0.4)	8 (3)	12 (1.1)	1 (0.8)	0.005
• <i>Streptococcus pyogenes</i>	10 (1.2)	5 (1.9)	1 (0.1)	0 (0)	0.003
• <i>Streptococcus pneumoniae</i>	0 (0)	10 (3.8)	2 (0.2)	0 (0)	<0.001
• <i>Streptococcus dysgalactiae</i>	2 (0.2)	7 (2.6)	1 (0.1)	0 (0)	<0.001
<i>Enterococcus</i> species	106 (12.6)	6 (2.3)	66 (6.3)	4 (3.2)	<0.001
• <i>Enterococcus faecalis</i>	95 (11.3)	5 (1.9)	55 (5.2)	3 (2.4)	<0.001
• <i>Enterococcus faecium</i>	7 (0.8)	1 (0.4)	5 (0.5)	0 (0.0)	0.584

\* Percentages marked in bolded blue are statistically significant highest percentages in that row. Two percentages marked in bolded blue in the same row refer to the highest percentages (both are significantly higher than the other two percentages), but with no statistically significant differences between them.

**Table 3.** Microorganisms and group of microorganisms (other than aerobic Gram-positive cocci) involved in prosthetic joint infections according to the four categories of the Tsukayama classification.

Microorganism or Microorganism Group	Early Postoperative Infections n = 839	Acute Hematogenous Infections n = 265	Late Chronic Infections n = 1052	Positive Intraoperative Cultures n = 126	p-Value
	Total no. (%)*				
Aerobic Gram-negative bacilli					
• Enterobacteriaceae	395 (47.1)	60 (22.6)	161 (15.3)	14 (11.1)	<0.001
○ <i>Escherichia coli</i>	303 (36.1)	49 (18.5)	106 (10.1)	6 (4.8)	<0.001
○ <i>Proteus</i> spp.	129 (15.4)	33 (12.5)	41 (3.9)	3 (2.4)	<0.001
○ <i>Enterobacter</i> spp.	75 (8.9)	4 (1.5)	27 (2.6)	2 (1.6)	<0.001
○ <i>Klebsiella</i> spp.	73 (8.7)	5 (1.9)	19 (1.8)	0 (0)	<0.001
○ <i>Morganella morganii</i>	48 (5.7)	1 (0.4)	1 (0.4)	9 (0.9)	<0.001
○ <i>Serratia marcescens</i>	26 (3.1)	4 (1.5)	11 (1)	1 (0.8)	=0.009
○ Non-fermenting Gram-negative bacilli	13 (1.5)	0 (0)	6 (0.6)	0 (0)	=0.028
○ <i>Pseudomonas</i> spp.	137 (16.3)	9 (3.4)	62 (5.9)	9 (7.1)	<0.001
○ <i>Acinetobacter</i> spp.	128 (15.3)	8 (3)	59 (5.6)	6 (4.8)	<0.001
Aerobic Gram-positive bacilli	10 (1.2)	0 (0)	2 (0.2)	1 (0.8)	0.021
• <i>Corynebacterium</i> species	16 (1.9)	5 (1.9)	29 (2.8)	4 (3.2)	0.555
○ <i>Corynebacterium striatum</i>	16 (1.9)	1 (0.4)	29 (2.8)	4 (3.2)	0.087
○ <i>Corynebacterium</i> spp. without identification to species level	9 (1.1)	0 (0)	7 (0.7)	1 (0.8)	0.321
Anaerobic Gram-positive bacilli	19 (2.3)	3 (1.1)	73 (6.9)**	22 (17.3)**	<0.001
• <i>Cutibacterium</i> spp.	17 (2)	3 (1.1)	64 (6.1)**	19 (15.1)**	<0.001
Anaerobic Gram-positive cocci†	8 (1)	2 (0.8)	23 (2.2)	0 (0)	0.042
Anaerobic Gram-negative bacilli	12 (1.4)	1 (0.4)	8 (0.8)	0 (0)	0.182
• <i>Bacteroides</i> group	10 (1.1)	1 (0.3)	5 (0.4)	0 (0)	0.145
<i>Mycobacterium</i> species	2 (0.2)	0 (0)	8 (0.8)	0 (0)	0.183
Fungi	8 (1.5)	4 (1.5)	16 (1.5)	2 (1.6)	0.723
• <i>Candida</i> spp.	8 (1)	3 (1.1)	14 (1.3)	2 (1.6)	0.854
Multidrug-resistant organisms	201 (24)	29 (10.9)	82 (7.8)	6 (4.8)	<0.001
• Methicillin-resistant <i>S. aureus</i>	92 (11)	22 (8.3)	58 (5.5)	5 (4)	<0.001
• Multidrug-resistant Gram-negative bacilli	112 (13.3)	7 (2.6)	25 (2.4)	1 (0.8)	<0.001
• Extended-spectrum beta-lactamase producing <i>Enterobacteriaceae</i>	36 (4.3)	2 (0.8)	4 (0.4)	0 (0.0)	<0.001
Ciprofloxacin-resistant Gram-negative bacilli	63 (7.5)	7 (2.6)	20 (1.9)	3 (2.4)	<0.001
Polymicrobial infections	230 (27.4)**	17 (6.3)	143 (13.1)**	7 (5.6)	<0.001

\* Percentages marked in bolded blue are the highest statistically significant percentages in that row. Two percentages marked in bolded blue in the same row with no other marks, refer to the highest percentages (both are significantly higher than the other two percentages), but with no statistically significant differences between them. \*\* The two highest percentages in that row but with statistically significant differences between them. † *Finegoldia magna* 5, *Parvimonas micra* 5, *Peptostreptococcus anaerobius* 3, *Peptococcus niger* 4, *Peptostreptococcus* not identified to species level 15.


With respect to non-haematogenous infections, a microbiological diagnosis was obtained for 94.5%, 92.7%, 92%, and 88.2% of cases in the first month, months 2/3, 4–12 and more than 12 months after index surgery, respectively, with a statistically significant decreasing linear trend ( $p < 0.001$ ). With respect to PJIs diagnosed in the first month after surgery (EPI according to the Tsukayama classification) versus those diagnosed in the second or third month after surgery (also early infections according to other common classifications) [5,36], the former were significantly more often caused by *S. aureus*, enterococci, aerobic GNB (with more than twice the percentage of both *Enterobacteriaceae* and non-fermenting GNB than in months 2 and 3), MDROs (both MRSA and multidrug-resistant GNB, including ESBL-producing *Enterobacteriaceae*) and polymicrobial infections, and less often caused by CoNS, streptococci, and *Cutibacterium* spp. (Table 4). Furthermore, infections diagnosed more than three months after surgery were more frequently caused by CoNS, and less commonly by *Enterobacteriaceae* than those diagnosed in the first two to three months after surgery. No other differences between these four time intervals were observed. When the four periods of time after the index surgery were considered overall, a statistically significant decreasing linear trend was observed for infections caused by *S. aureus*, enterococci, *Enterobacteriaceae*, non-fermenting GNB (mainly *Pseudomonas* spp.), MDROs (both MRSA and multidrug-resistant GNB), and polymicrobial infections ( $p < 0.001$  in each case) and a rising trend for infections caused by CoNS ( $p < 0.001$ ), streptococci ( $p = 0.015$ ) and anaerobic bacteria (mainly *Cutibacterium* spp.) ( $p < 0.001$ ).

**Table 4.** Microorganisms and groups of organisms involved in non-hematogenous prosthetic joint infections according to time of infection after surgery ( $\leq 1$  month, 2–3 months, 4–12 months,  $> 12$  months).

Microorganism or Microorganism Group	PJI within 1 Month after Surgery n = 844	PJI 2–3 Months after Surgery n = 243	PJI 4–12 Months after Surgery n = 277	PJI $> 12$ Months after Surgery n = 619	p-Value
Total no. (%)*					
<i>Staphylococcus</i> species					
• Coagulase-negative staphylococci	236 (28.2) **	107 (44) ** †	167 (60.3) †	348 (56.2)	<0.001
○ <i>Staphylococcus epidermidis</i>	132 (15.6) **	68 (28) ** †	106 (38.3) †	203 (32.8)	<0.001
○ <i>Staphylococcus lugdunensis</i>	2 (0.2) **	3 (1.3) **	10 (3.6)	22 (3.6)	<0.001
• <i>Staphylococcus aureus</i>	301 (35.7)	60 (24.7)	60 (21.7)	108 (17.4)	<0.001
<i>Streptococcus</i> species	36 (4.3) **	25 (10.3) **	14 (5.1)	49 (7.9)	<0.001
○ <i>Streptococcus agalactiae</i>	8 (0.9) **	11 (4.5) **	6 (2.2)	10 (1.6)	0.003
○ Viridans group streptococci not identified to species level	6 (0.7) **	7 (2.9) **	2 (0.7) †	18 (2.9) †	0.003
<i>Enterococcus</i> species	106 (12.6)	23 (9.5)	15 (5.4)	32 (5.4)	<0.001
Aerobic Gram-negative bacilli					
• <i>Enterobacteriaceae</i>	396 (46.9) **	50 (20.6) ** †	37 (13.4) †	37 (13.4)	<0.001
○ <i>Escherichia coli</i>	303 (35.9) **	37 (15.2) ** †	25 (9) †	48 (7.8)	<0.001
○ <i>Proteus</i> spp.	129 (15.3)	12 (4.9)	10 (3.6)	21 (3.4)	<0.001
○ <i>Enterobacter</i> spp.	75 (8.9)	7 (2.9)	7 (2.5)	14 (2.3)	<0.001
○ <i>Klebsiella</i> spp.	73 (8.6) **	11 (4.5) ** †	2 (0.7) †	6 (1)	<0.001
• Non-fermenting Gram-negative bacilli	48 (5.7)	2 (0.8)	4 (1.4)	3 (0.5)	<0.001
○ <i>Pseudomonas</i> spp.	138 (16.4) **	16 (6.6) **	11 (4)	41 (6.6)	<0.001
Aerobic Gram-positive bacilli	128 (15.2) **	17 (7) **	11 (4)	35 (5.7)	<0.001
Anaerobic Gram-positive bacilli					
• <i>Cutibacterium</i> spp.	16 (1.9)	3 (1.2)	7 (2.5)	23 (3.7)	0.083
Anaerobic Gram-positive cocci	19 (2.3) **	14 (5.7) **	16 (5.8)	61 (9.7)	<0.001
Anaerobic Gram-negative bacilli	17 (2) **	12 (4.9) **	16 (5.8)	51 (8.2)	<0.001
<i>Mycobacterium</i> species					
Fungi	8 (0.9)	3 (1.2)	3 (1.1)	12 (1.9)	0.418
Multidrug-resistant organisms					
• Methicillin-resistant <i>S. aureus</i>	202 (23.9)	20 (8.2)	20 (7.2)	43 (6.9)	<0.001
• Multidrug-resistant Gram-negative bacilli	93 (11)	14 (5.8)	14 (5.1)	30 (4.8)	<0.001
• Extended-spectrum beta-lactamases producing <i>Enterobacteriaceae</i>	112 (13.3)	7 (2.5)	5 (1.8)	14 (2.3)	<0.001
Ciprofloxacin-resistant Gram-negative bacilli	36 (4.3)	1 (0.4)	2 (0.7)	1 (0.3)	<0.001
Polymicrobial infections	84 (10)	5 (2.1)	4 (1.4)	11 (1.8)	<0.001

\* Percentages marked in bolded blue are the highest statistically significant percentages in that row. Two percentages marked in bolded blue in the same row with no other indication refer to the highest percentages (both are significantly higher than the other two percentages) with no statistically significant differences between them. \*\* and † indicate adjacent percentages with statistically significant differences between them in the same row.

Figure 1 shows the main microorganisms/groups of organisms involved in each of the Tsukayama categories of PJI (A) and in non-haematogenous PJs according to time since index surgery (B).



**Figure 1.** Main microorganisms or group of microorganisms involved in prosthetic joint infections according to Tsukayama's classification (A), and in non-hematogenous prosthetic joint infection according to time since index surgery (B).

#### 4. Discussion

Empirical antimicrobial treatment is based on a diagnosis of infection without knowing the causative microorganism, while covering those most likely to be involved in particular clinical situations [42]. This multicenter study, which is, to our knowledge the largest series to have analyzed this question, found significant differences in the microbial etiology of different types of prosthetic joint infection. Our results show that the choice of empirical antibiotics for early postoperative infections (EPI) (<1 month after surgery) is the most challenging, since these infections are characterized by a preponderance of diverse and virulent pathogens, mainly *S. aureus*, *Enterobacteriaceae*, *Pseudomonas aeruginosa* and enterococci, MDROs, and polymicrobial infections. These microorganisms and groups of organisms were isolated progressively less frequently in non-hematogenous PJs after the first month following index surgery, whereas a steady linear increase over time was observed for less

virulent microorganisms, such as CoNS and *Cutibacterium* spp. (frequently considered commensals). Multidrug-resistant GNB were rarely encountered in non-EPI infections, and MRSA was isolated twice as frequently in EPIs as in LCIs. The pattern for AHI was different, with *S. aureus* and streptococci together accounting for almost 70% of infections. These results could help in the selection of an empirical antimicrobial therapy that is tailored to specific clinical situations, with coverage of the most likely microorganisms, but the narrowest possible antimicrobial spectrum.

As in other previous series, the most commonly cultured microorganisms in PJIs belonged to the CoNS group (with *S. epidermidis* the most common species) [38]. These bacteria are ubiquitous members of the human skin microbiome and lack aggressive virulence properties overall, but nevertheless account for the most device-associated infections, mainly because of their capacity for biofilm production [43]. These characteristics would explain our finding of CoNS as a common cause of perioperatively-acquired PJI, with clinical manifestations increasingly more common after the early postoperative period, but rarely a cause of AHI. In spite of significant differences between the CoNS species [43], we found that isolates of CoNS species behaved in a similar way, although it should be remembered that a substantial percentage of CoNS were not identified to the species level.

As in nearly all previous series, *S. aureus* was the most common bacterial species found as a cause of PJI (followed by *S. epidermidis*) [44,45]. *S. aureus* was the most frequently found causative pathogen of AHI, probably because of its high virulence. In previous studies, PJI following *S. aureus* bacteremia was observed in 30 to 40% of patients with prosthetic joints. Furthermore, non-hematogenous PJIs caused by *S. aureus* most often presented early [45]; our results showed a linear percentage decrease in *S. aureus* after the first month post-surgery.

Overall, streptococci and enterococcus species cause only 9% and 8% of PJIs, respectively, and are more often involved in acute than chronic infections. However, while streptococci are found in a noteworthy 30% of AHI (the second most common cause of this type of infection after *S. aureus*), enterococci are more common in EPI, although only accounting for 13% of these infections, a similar percentage to those observed in other studies of EPI [12,29,46].

Aerobic GNB were found in 47% of EPIs using the Tsukayama classification, and 41.1% when considering infections that presented within 90 days of surgery. This is a high proportion, similar to percentages observed in other recent studies of PJI diagnosed in the first 3 months after surgery (39–42%) [11,47]. GNB have been considered an infrequent cause of PJI in the classic series, accounting for less than 10% of cases [41], although few studies have focused specifically on the etiology of PJI across the full range of infections, or were performed a long time ago, since when the microbiology of PJI is likely to have changed [8,14,41]. Nevertheless, the type of infection should always be taken into consideration. Accordingly, we observed that after the first month post-surgery, the percentage of non-hematogenous GNB PJIs steadily declined to 13.4% after the third month, which approaches the percentages found in the classic series.

*C. acnes* is a major colonizer of the human skin that has recently emerged as a significant opportunistic pathogen able to cause implant-associated infections, typically with fewer clinical manifestations of infection than other bacteria [48]. This may explain why it was unexpectedly found more often in revision surgery (PIC) in our results than in other types of infection.

As in previous studies, polymicrobial PJI was much more frequently found in EPI than in any other type [8]; the percentages of polymicrobial AHI and PIC cases were very low and the proportion of non-hematogenous polymicrobial PJIs decreased over time after the index surgery.

MDROs, which included mainly MRSA and multidrug-resistant GNB, were isolated in almost a quarter of EPIs, but rarely in other types of infection. Since no previous studies have studied the involvement of MDROs, and GNB especially, in terms of the category of infection, these results should be corroborated by other studies. Although the local epidemiology of MDROs will vary [49], our results suggest that, overall, they are more often isolated in EPIs.

Based on our findings, some recommendations can be made for empirical antimicrobial treatment of PJIs. The regimen for a non-hematogenous PJI diagnosed in the first month following surgery should

cover staphylococci, including methicillin-resistant staphylococci (with vancomycin or antibiotics with a similar spectrum, such as other glycopeptides or daptomycin) as well as *Enterobacteriaceae* and *P. aeruginosa* (with an antipseudomonal cephalosporin such as cefepime or ceftazidime). Overall, it seems that a broader-spectrum beta-lactam (such as piperacillin/tazobactam or a carbapenem) is not needed because of the low proportion of anaerobes and ESBL-*Enterobacteriaceae*. Likewise, in patients with non-hematogenous PJs diagnosed in the second or third month after surgery, empirical regimens should also include methicillin-resistant staphylococci and *Enterobacteriaceae*, although coverage of *P. aeruginosa* may be unnecessary, and a third-generation non-antipseudomonal cephalosporin (ceftriaxone/cefotaxime) could be used instead of cefepime/ceftazidime. For non-hematogenous PJs arising after the third month, empirical coverage of GNB (*Enterobacteriaceae* and *P. aeruginosa*) may not be required, also bearing in mind that these PJs require removal of the prosthesis and the initial empirical therapy may not be so critical in this situation (although this issue has not so far been studied). For hematogenous infections, empirical treatment against *S. aureus*, streptococci, and *E. coli* (with a low percentage of multidrug-resistant *Enterobacteriaceae*) is recommended; coverage of MRSA should be considered even though this pathogen represents less than 10% of cases, because of the high mortality associated with MRSA bacteremia (which rises with inappropriate empirical therapy) [45]. Hence, a regimen including vancomycin (other glycopeptides/daptomycin) and ceftriaxone/cefotaxime could be envisaged. Empirical treatment may be needed for PIC until antibiogram data is available and coverage of methicillin-resistant staphylococci should be considered; it should also be borne in mind that *C. acnes* is usually susceptible to penicillin [43]. Despite the undoubted importance of rifampin and quinolones in the treatment of PJI, these agents are not recommended during the initial treatment phase of infection [2,6]. A preoperative synovial fluid culture is helpful for identification of the causative microorganism and determination of their antimicrobial susceptibility and, in addition, for informing the choice of postoperative antimicrobials. This can be very useful in chronic infections; although less so in acute infections since antimicrobial therapy is commonly started before the culture results are available. Nevertheless, a perioperative aspiration culture has shown a moderate average sensitivity of 68% [50].

There is at present no universally accepted classification of PJI [8,16]. The best classifications would be useful for therapeutic decision making, such as deciding on surgical treatment (debridement and implant retention or device removal) and starting appropriate empirical antimicrobial treatment. Following the Tsukayama scheme, EPI and AHI can potentially be cured with debridement and implant retention, while LCI requires prosthesis removal for cure. In the case of PIC, the surgical decision has already been made. Furthermore, each category of infection has a specific etiological pattern that facilitates tailored empirical treatment. LCIs presenting in months two to three and more than three months after surgery have different microbiological characteristics (mainly based on a significant difference in the incidence of CoNS and *Enterobacteriaceae*), which may allow empirical treatment to be refined. A new category that includes the two to three month postoperative period should therefore be considered. This new category is of further interest due to the possibility of curing PJs without removal of the prosthesis during this period [6,51].

The limitations of our study are mainly related to its partial retrospective design, although it would be very difficult to collect such a large number of PJI cases with any other. The study assesses the microbial etiology of PJs in our country and our results may not be generalizable to other countries, although other studies in different areas of the world have shown comparable results in many respects. Another strength of our study is its use of a standardized definition of MDRO [39], which enables comparisons of results with other centers. This definition of MDRO, however, has limitations in the context of PJI, since it does not include a definition of multidrug-resistant CoNS [39]. Nevertheless, the vast majority of clinically recovered CoNS isolates are methicillin-resistant [38], which determines the empirical treatment of PJs. Our study also included all consecutive patients with a diagnosis of PJI, avoiding potential inclusion bias and guaranteeing that the various categories of infection were adequately represented.

Our study provides detailed, comprehensive information about the microbial etiology of different categories of PJI. Notable differences in the causative microorganisms of these types of infection were found, which could be useful for optimizing empirical antimicrobial therapy of PJI and for improving the outcome of these infections. The Tsukayama classification is a useful guide for the treatment of PJI, although an extra category specific to non-hematogenous infections presenting in the second and third month after surgery should be considered.

**Author Contributions:** Conceptualization, N.B., I.M., P.C., X.C. and J.A.; Data curation, N.B., I.M., A.R. (Alba Ribera), A.S., D.R.-P., L.S., J.C., M.F.-S., M.D.d.T., L.G., J.P., A.B., M.R., J.E., J.M.B.-E., J.M.-A., A.J.-S., C.D., A.R. (Antonio Ramos), B.S., G.E., L.M., C.P. and J.P.H.; Formal analysis, N.B.; Funding acquisition, N.B.; Investigation, N.B., I.M., A.R. (Alba Ribera), A.S., D.R.-P., L.S., J.C., M.F.-S., M.D.d.T., L.G., J.P., A.B., M.R., J.E., J.M.B.-E., J.M.-A., A.J.-S., C.D., A.R. (Antonio Ramos), B.S., G.E., L.M., C.P., J.P.H., P.C., X.C. and J.A.; Methodology, N.B., J.C., M.D.d.T., C.P., P.C. and J.A.; Project administration, N.B.; Resources, I.M., A.R. (Alba Ribera) and L.S.; Supervision, N.B., I.M., A.S., D.R.-P., J.C., M.D.d.T., L.G., M.R., J.E., A.J.-S., G.E., C.P., J.P.H., X.C. and J.A.; Validation, N.B., I.M., A.S., D.R.-P., L.S., J.C., M.F.-S., M.D.d.T., J.P., A.B., M.R., J.E., J.M.B.-E., J.M.-A., C.D., An.R., B.S., G.E., L.M. and J.P.H.; Writing—original draft, N.B.; Writing—review & editing, N.B., I.M., A.R. (Alba Ribera), A.S., D.R.-P., L.S., J.C., M.F.-S., M.D.d.T., L.G., J.P., A.B., M.R., J.E., J.M.B.-E., J.M.-A., A.J.-S., C.D., A.R. (Antonio Ramos), B.S., G.E., L.M., C.P., J.P.H., P.C., X.C. and J.A.

**Acknowledgments:** This work was supported by the Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness (grant number PI15/1026) (Co-funded by European Regional Development Fund/European Social Fund "Investing in your future"). REIPI (Spanish Network for Research in Infectious Disease) is supported by the Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, and by the European Development Regional Fund "A way to achieve Europe".

**Conflicts of Interest:** The authors declare no conflict of interests relevant to this article.

## References

- Schwarz, E.M.; Parvizi, J.; Gehrke, T.; Aiyer, A.; Battenberg, A.; Brown, S.A.; Callaghan, J.J.; Citak, M.; Egol, K.; Garrigues, G.E.; et al. 2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions. *J. Orthop. Res.* **2019**, *37*, 997–1006. [[CrossRef](#)] [[PubMed](#)]
- Peel, T.N. Studying Biofilm and Clinical Issues in Orthopedics. *Front. Microbiol.* **2019**, *10*. [[CrossRef](#)] [[PubMed](#)]
- Saeed, K.; McLaren, A.C.; Schwarz, E.M.; Antoci, V.; Arnold, W.V.; Chen, A.F.; Clauss, M.; Esteban, J.; Gant, V.; Hendershot, E.; et al. 2018 International Consensus Meeting on Musculoskeletal Infection: Summary from the biofilm workgroup and consensus on biofilm related musculoskeletal infections. *J. Orthop. Res.* **2019**, *37*, 1007–1017. [[CrossRef](#)] [[PubMed](#)]
- Zimmerli, W.; Sendi, P. Orthopaedic biofilm infections. *APMIS* **2017**, *125*, 353–364. [[CrossRef](#)] [[PubMed](#)]
- Tande, A.J.; Gomez-Urena, E.O.; Berbari, E.F.; Osmon, D.R. Management of prosthetic joint infection. *Infect. Dis. Clin. North Am.* **2017**, *31*, 237–252. [[CrossRef](#)]
- Ariza, J.; Cobo, J.; Baraia-Etxaburu, J.; Benito, N.; Bori, G.; Cabo, J.; Corona, P.; Esteban, J.; Horcajada, J.P.; Lora-Tamayo, J.; et al. Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). *Enferm. Infect. Microbiol. Clin.* **2017**, *35*, 189–195. [[CrossRef](#)]
- Osmon, D.R.; Berbari, E.F.; Berendt, A.R.; Lew, D.; Zimmerli, W.; Steckelberg, J.M.; Rao, N.; Hanssen, A.; Wilson, W.R. Infectious Diseases Society of America Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. *Clin. Infect. Dis.* **2013**, *56*, e1–e25. [[CrossRef](#)]
- Tande, A.J.; Patel, R. Prosthetic Joint Infection. *Clin. Microbiol. Rev.* **2014**, *27*, 302–345. [[CrossRef](#)]
- Sendi, P.; Zimmerli, W. Antimicrobial treatment concepts for orthopaedic device-related infection. *Clin. Microbiol. Infect.* **2012**, *18*, 1176–1184. [[CrossRef](#)]
- Leekha, S.; Terrell, C.L.; Edson, R.S. General principles of antimicrobial therapy. *Mayo Clin. Proc.* **2011**, *86*, 156–167. [[CrossRef](#)]
- Peel, T.N.; Cheng, A.C.; Choong, P.F.M.; Busing, K.L. Early onset prosthetic hip and knee joint infection: treatment and outcomes in Victoria, Australia. *J. Hosp. Infect.* **2012**, *82*, 248–253. [[CrossRef](#)]

12. Triffault-Fillit, C.; Ferry, T.; Laurent, F.; Pradat, P.; Dupieux, C.; Conrad, A.; Becker, A.; Lustig, S.; Fessy, M.H.; Chidiac, C.; et al. Microbiologic epidemiology depending on time to occurrence of prosthetic joint infection: a prospective cohort study. *Clin. Microbiol. Infect.* **2019**, *25*, 353–358. [[CrossRef](#)]
13. Triffault-Fillit, C.; Valour, F.; Guillot, R.; Tod, M.; Goutelle, S.; Lustig, S.; Fessy, M.-H.; Chidiac, C.; Ferry, T.; Ferry, T.; et al. Prospective cohort study of the tolerability of prosthetic joint infection empirical antimicrobial therapy. *Antimicrob. Agents Chemother.* **2018**, *62*. [[CrossRef](#)] [[PubMed](#)]
14. Benito, N.; Franco, M.; Ribera, A.; Soriano, A.; Rodriguez-Pardo, D.; Sorlí, L.; Fresco, G.; Fernández-Sampedro, M.; Dolores Del Toro, M.; Guío, L.; et al. Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study. *Clin. Microbiol. Infect.* **2016**, *22*, 732.e1–732.e8. [[CrossRef](#)] [[PubMed](#)]
15. Tsukayama, D.T.; Estrada, R.; Gustilo, R.B. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. *J. Bone Joint Surg. Am.* **1996**, *78*, 512–523. [[CrossRef](#)] [[PubMed](#)]
16. Parvizi, J.; Tan, T.L.; Goswami, K.; Higuera, C.; Della Valle, C.; Chen, A.F.; Shohat, N. The 2018 definition of periprosthetic hip and knee infection: An evidence-based and validated criteria. *J. Arthroplasty* **2018**, *33*, 1309–1314.e2. [[CrossRef](#)] [[PubMed](#)]
17. Bengtson, S.; Knutson, K. The infected knee arthroplasty. *Acta Orthop. Scand.* **1991**, *62*, 301–311. [[CrossRef](#)] [[PubMed](#)]
18. Berbari, E.F.; Hanssen, A.D.; Duffy, M.C.; Steckelberg, J.M.; Ilstrup, D.M.; Harmsen, W.S.; Osmon, D.R. Risk factors for prosthetic joint infection: case-control study. *Clin. Infect. Dis.* **1998**, *27*, 1247–1254. [[CrossRef](#)]
19. Segawa, H.; Tsukayama, D.T.; Kyle, R.F.; Becker, D.A.; Gustilo, R.B. Infection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infections. *J. Bone Joint Surg. Am.* **1999**, *81*, 1434–1445. [[CrossRef](#)]
20. Steckelberg, J.; Osmon, D.R. Prosthetic Joint Infections. In *Infections Associated with Indwelling Medical Devices*; Waldvogel, F.A., Bisno, A.L., Eds.; American Society of Microbiology: Washington, DC, USA, 2000; pp. 173–209.
21. Soriano, A.; Garcia, S.; Bori, G. Treatment of acute post-surgical infection of joint arthroplasty. *Clin. Microbiol. Infect.* **2006**, *12*, 930–933. [[CrossRef](#)]
22. Marculescu, C.E.; Berbari, E.F.; Hanssen, A.D.; Steckelberg, J.M.; Harmsen, S.W.; Mandrekar, J.N.; Osmon, D.R. Outcome of prosthetic joint infections treated with debridement and retention of components. *Clin. Infect. Dis.* **2006**, *42*, 471–478. [[CrossRef](#)] [[PubMed](#)]
23. Pandey, R.; Berendt, A.R.; Athanasou, N.A. Histological and microbiological findings in non-infected and infected revision arthroplasty tissues. *Arch. Orthop. Trauma Surg.* **2000**, *120*, 570–574. [[CrossRef](#)] [[PubMed](#)]
24. Pulido, L.; Ghanem, E.; Joshi, A.; Purtill, J.J.; Parvizi, J. Periprosthetic joint infection: The incidence, timing, and predisposing factors. *Clin. Orthop. Relat. Res.* **2008**, *466*, 1710–1715. [[CrossRef](#)] [[PubMed](#)]
25. Schäfer, P.; Fink, B.; Sandow, D.; Margull, A.; Berger, I.; Frommelt, L. Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. *Clin. Infect. Dis.* **2008**, *47*, 1403–1409. [[CrossRef](#)] [[PubMed](#)]
26. Sharma, D.; Douglas, J. Microbiology of infected arthroplasty: implications for empiric peri-operative antibiotics. *J. Orthop. Surg. (Hong Kong)* **2008**, *16*, 339–342. [[CrossRef](#)]
27. Lee, J.; Kang, C.-I.; Lee, J.H.; Joung, M.; Moon, S.; Wi, Y.M.; Chung, D.R.; Ha, C.-W.; Song, J.-H.; Peck, K.R. Risk factors for treatment failure in patients with prosthetic joint infections. *J. Hosp. Infect.* **2010**, *75*, 273–276. [[CrossRef](#)]
28. Berbari, E.F.; Osmon, D.R.; Carr, A.; Hanssen, A.D.; Baddour, L.M.; Greene, D.; Kupp, L.I.; Baughan, L.W.; Harmsen, W.S.; Mandrekar, J.N.; et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. *Clin. Infect. Dis.* **2010**, *50*, 8–16. [[CrossRef](#)]
29. Cobo, J.; Miguel, L.G.S.; Euba, G.; Rodríguez, D.; García-Lechuz, J.M.M.; Riera, M.; Falgueras, L.; Palomino, J.; Benito, N.; del Toro, M.D.D.; et al. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. *Clin. Microbiol. Infect.* **2011**, *17*, 1632–1637. [[CrossRef](#)]
30. Wang, F.-D.; Wang, Y.-P.; Chen, C.-F.; Chen, H.-P. The incidence rate, trend and microbiological aetiology of prosthetic joint infection after total knee arthroplasty: A 13 years' experience from a tertiary medical center in Taiwan. *J. Microbiol. Immunol. Infect.* **2018**, *51*, 717–722. [[CrossRef](#)]
31. Moran, E.; Masters, S.; Berendt, A.R.; McLardy-Smith, P.; Byren, I.; Atkins, B.L. Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. *J. Infect.* **2007**, *55*, 1–7. [[CrossRef](#)]

32. Zeller, V.; Kerroumi, Y.; Meyssonnier, V.; Heym, B.; Metten, M.-A.; Desplaces, N.; Marmor, S. Analysis of postoperative and hematogenous prosthetic joint-infection microbiological patterns in a large cohort. *J. Infect.* **2018**, *76*, 328–334. [CrossRef] [PubMed]
33. Peel, T.N.; Cheng, A.C.; Busing, K.L.; Choong, P.F.M. Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective? *Antimicrob. Agents Chemother.* **2012**, *56*, 2386–2391. [CrossRef] [PubMed]
34. Rodríguez, D.; Pigrau, C.; Euba, G.; Cobo, J.; García-Lechuz, J.; Palomino, J.; Riera, M.; del Toro, M.D.; Granados, A.; Ariza, X. Acute haematogenous prosthetic joint infection: prospective evaluation of medical and surgical management. *Clin. Microbiol. Infect.* **2010**, *16*, 1789–1795. [CrossRef] [PubMed]
35. Rodríguez-Pardo, D.; Pigrau, C.; Lora-Tamayo, J.; Soriano, A.; del Toro, M.D.; Cobo, J.; Palomino, J.; Euba, G.; Riera, M.; Sánchez-Somolinos, M.; et al. Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. *Clin. Microbiol. Infect.* **2014**, *20*, O911–O919. [CrossRef] [PubMed]
36. Lora-Tamayo, J.; Murillo, O.; Iribarren, J.A.; Soriano, A.; Sánchez-Somolinos, M.; Baraia-Etxaburu, J.M.; Rico, A.; Palomino, J.; Rodríguez-Pardo, D.; Horcajada, J.P.; et al. A large multicenter study of methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* prosthetic joint infections managed with implant retention. *Clin. Infect. Dis.* **2013**, *56*, 182–194. [CrossRef] [PubMed]
37. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J. Chronic Dis.* **1987**, *40*, 373–383. [CrossRef]
38. Parvizi, J.; Zmistowski, B.; Berbari, E.F.; Bauer, T.W.; Springer, B.D.; Della Valle, C.J.; Garvin, K.L.; Mont, M.A.; Wongworawat, M.D.; Zalavras, C.G. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. *Clin. Orthop. Relat. Res.* **2011**, *469*, 2992–2994. [CrossRef] [PubMed]
39. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* **2012**, *18*, 268–281. [CrossRef] [PubMed]
40. Tsukayama, D.T.; Goldberg, V.M.; Kyle, R. Diagnosis and management of infection after total knee arthroplasty. *J. Bone Joint Surg. Am.* **2003**, *85*, S75–S80. [CrossRef]
41. Zimmerli, W.; Trampuz, A.; Ochsner, P.E. Prosthetic-joint infections. *N. Engl. J. Med.* **2004**, *351*, 1645–1654. [CrossRef]
42. Høiby, N.; Bjarnsholt, T.; Moser, C.; Bassi, G.L.L.; Coenye, T.; Donelli, G.; Hall-Stoodley, L.; Holá, V.; Imbert, C.; Kirketerp-Møller, K.; et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. *Clin. Microbiol. Infect.* **2015**, *21*, S1–S25. [CrossRef]
43. Becker, K.; Heilmann, C.; Peters, G. Coagulase-negative staphylococci. *Clin. Microbiol. Rev.* **2014**, *27*, 870–926. [CrossRef]
44. Kahl, B.C.; Becker, K.; Löffler, B. Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections. *Clin. Microbiol. Rev.* **2016**, *29*, 401–427. [CrossRef]
45. Tong, S.Y.C.; Davis, J.S.; Eichenberger, E.; Holland, T.L.; Fowler, V.G. *Staphylococcus aureus* Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management. *Clin. Microbiol. Rev.* **2015**, *28*, 603–661. [CrossRef] [PubMed]
46. Tornero, E.; Morata, L.; Martínez-Pastor, J.C.; Bori, G.; Climent, C.; García-Velez, D.M.; García-Ramiro, S.; Bosch, J.; Mensa, J.; Soriano, A. KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. *Clin. Microbiol. Infect.* **2015**, *21*, 786.e9–786.e17. [CrossRef]
47. Tornero, E.; Martínez-Pastor, J.C.; Bori, G.; García-Ramiro, S.; Morata, L.; Bosch, J.; Mensa, J.; Soriano, A. Risk factors for failure in early prosthetic joint infection treated with debridement. Influence of etiology and antibiotic treatment. *J. Appl. Biomater. Funct. Mater.* **2014**, *12*, 129–134. [CrossRef] [PubMed]
48. Achermann, Y.; Goldstein, E.J.C.; Coenye, T.; Shirtliff, M.E. *Propionibacterium acnes*: From Commensal to opportunistic biofilm-associated implant pathogen. *Clin. Microbiol. Rev.* **2014**, *27*, 419–440. [CrossRef]
49. Aggarwal, V.K.; Bakhshi, H.; Ecker, N.U.; Parvizi, J.; Gehrke, T.; Kendoff, D. Organism profile in periprosthetic joint infection: pathogens differ at two arthroplasty infection referral centers in Europe and in the United States. *J. Knee Surg.* **2014**, *27*, 399–406. [CrossRef]

50. Rodriguez-Merchan, E.C. Preoperative aspiration culture (PAC) for the diagnosis of infection in a prosthetic knee joint. *Arch. Bone Jt. Surg.* **2018**, *6*, 342–345. [[PubMed](#)]
51. Lora-Tamayo, J.; Senneville, É.; Ribera, A.; Bernard, L.; Dupon, M.; Zeller, V.; Li, H.K.H.K.; Arvieux, C.; Clauss, M.; Uçkay, I.; et al. The Not-So-Good Prognosis of Streptococcal Periprosthetic Joint Infection Managed by Implant Retention: The Results of a Large Multicenter Study. *Clin. Infect. Dis.* **2017**, *64*, 1742–1752. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).